Navigation Links
Regulatory Path for Bronchitol in Bronchiectasis
Date:5/1/2008

rrently in the later stages of development for bronchiectasis. We are determined to make it available to patients worldwide as soon as possible."

Pharmaxis is developing Bronchitol as a treatment to improve mucus clearance in the lungs of patients with cystic fibrosis, bronchiectasis and chronic obstructive pulmonary diseases. Bronchitol is a patented, inhalable dry powder formulation of mannitol that is administered directly to the lungs through a convenient, breath activated and easy to use hand held device. The U.S. Food and Drug Administration has granted Bronchitol fast track status and it is designated as an orphan drug in the U.S. and Europe.

A large Phase III trial expected to form the basis of a marketing approval for Bronchitol in Europe in patients with cystic fibrosis is currently actively recruiting.

CONTACT: Alan Robertson - Chief Executive Officer

Ph: +61 2 9454 7200 or email alan.robertson@pharmaxis.com.au

Released through:

United States: Brandon Lewis, Trout Group, phone +1 646 378 2915 or email blewis@troutgroup.com

Australia:

Virginia Nicholls, phone +61 417 610 824 or email virginia.nicholls@pharmaxis.com.au

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
3. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
4. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
5. Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
6. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
7. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
8. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
9. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... TX (PRWEB) May 21, 2013 Smarter ... outdoor security solutions, today announced that Genzyme, a Sanofi ... units of Door Detective® CL for a multi-use facility ... installed in four other Genzyme buildings, this latest order ... with the tailgate detection device improving doorway ...
(Date:5/21/2013)... 2013  MacroGenics, Inc. today announced that an ... an Fc-modified chimeric monoclonal antibody (MAb), in patients ... will be presented at the 2013 Annual Meeting ... the Developmental Therapeutics - Immunotherapy Oral Abstract Session ... PM.  The presentation will describe the results of ...
(Date:5/21/2013)... May 21, 2013 NANONEX CORPORATION, ... solutions , today announced the successful delivery and ... system, the NX-M200B, to a major Japanese manufacturing ... a fully-automated, production-ready, advanced nanoimprint lithography tool that ... wafer and substrate sizes and types. Based on ...
(Date:5/21/2013)... 2013 PathoGenetix, Inc., a commercial-stage developer ... announced today that it has successfully identified and strain ... obtained from the Centers for Disease Control and Prevention ... The findings are detailed in a poster ... for Microbiology in Denver on Monday. , The 250 ...
Breaking Biology Technology:Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3
... (Nasdaq: BCRX ) today announced that it ... Industry conference in New,York. A live webcast of ... 2:00 p.m. Eastern Time may be accessed at ... be archived for seven days. (Logo: ...
... 30 Cepheid (Nasdaq:,CPHD) will present at the ... Four Seasons Hotel, Boston, September 5 to 7, ... Vice President, Finance and,Chief Financial Officer, John R. ... 7. The webcast, along with accompanying presentation ...
... Sciences,Holdings, Inc. (Nasdaq: ADLS ) today announced ... at the 2007 UBS Global Life Sciences,Conference which ... York on Wednesday,September 26 at 1:30 p.m. EDT. ... webcast of the presentation will be accessible through ...
Cached Biology Technology:BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference 2BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference 3Cepheid to Present at Thomas Weisel Partners Healthcare Conference 2Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference 2
(Date:5/18/2013)... Research presented today at Digestive Disease Week (DDW) ... about the impact of coffee on autoimmune disease and ... consumption recently has been associated with reduced risk of ... more cups of java each month also correlate with ... at the Mayo Clinic, Rochester, MN, linked coffee consumption ...
(Date:5/18/2013)... An increasing number of U.S. children are ... according to research presented at Digestive Disease Week ... researchers at the Cleveland Clinic Children,s Hospital found ... exhaled breath compared to their lean counterparts. The ... that can be correlated to potential complications associated ...
(Date:5/17/2013)... insects provide the white noise of the South, but the ... the Southern air hangs heavy from the humidity and the ... than 140 species of frogs, toads and salamanders, is the ... ponds and swamps are the auditorium for their symphonic choruses, ... Monitoring Initiative, or ARMI, have front-row seats. , ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4
... Research in Oral Biology Award will be presented to ... at the International Association for Dental Research (IADR) 87th ... 1, 2009. , Dr. McCulloch has been professor in ... He also serves as Director of,the Canadian Institutes of ...
... medulloblastoma, the most frequent malignant brain tumor in childhood, ... spread and what the chances of disease relapse are. ... at the Heidelberg University Hospital and the German Cancer ... set of tumor markers, the intensity of treatment can ...
... American Association for Cancer Research extends its sincere ... to lead the Food and Drug Administration (FDA). ... advancement of cutting-edge products and therapies that are ... Her leadership will bring new perspectives to important ...
Cached Biology News:New tumor markers determine therapy intensity 2New tumor markers determine therapy intensity 3
...
...
... robotic workstations is designed for laboratories with ... ideal automation platform for routine sample preparation ... improving throughput, process consistency and safety. ... allows you to control the robotic and ...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
Biology Products: